Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of REGN5069 in Healthy Volunteers
NCT03645746Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Nadecnemab in osteoarthritis (OA) (7 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 36 weeks, Incidence of laboratory abnormalities at 36 weeks and 2 more. Started Aug 2018; status: completed.
02
Drugs
Nadecnemab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03645746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645746.